BioSpace News Archive

Idorsia Pharmaceuticals US Inc. announced today its support of a clinical study sponsored by the U.S. Department of Defense (DOD) to develop new therapies to treat Posttraumatic Stress Disorder (PTSD).

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in the Stifel Jaws & Paws Conference on Wednesday, May 31, 2023.

Vakzine Projekt Management GmbH (VPM) is delighted to announce the successful licensing of the novel R21/Matrix-MTM Malaria Vaccine by the Ghana Food and Drugs Authority (FDA) for use in children as young as 5 months old up to 36 months old, in Ghana.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and investor in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company has established collaborations with several Tuberculosis (TB) medical care facilities to initiate the data collection and screening of active respiratory challenged patients.

KBI Biopharma Appoints Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific Officer.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

SeaStar Medical Holding Corporation announces that Eric Schlorff, CEO, will present a company overview at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 2:30 p.m. Eastern time.

Phathom Pharmaceuticals, Inc. today reported financial results for the first quarter of 2023 and provided updates on recent regulatory progress.

China SXT Pharmaceuticals, Inc. announced that on May 4, 2023, the Company received a written notification from the Nasdaq’s Listing Qualifications Department, granting the Company another 180 calendar days extension, or until October 30, 2023, to regain compliance with Nasdaq’s minimum bid price requirement.

Codagenix Inc. today announced that it has initiated dosing in a pediatric Phase 1 study evaluating CodaVax™-RSV, a live-attenuated, intranasal vaccine candidate for the prevention of disease caused by respiratory syncytial virus (RSV).